TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01010737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric-001 250 mcg
Description: Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Multimeric-001 250mcg
Description: Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant: Montonide isa 51 VG
Description: Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant: Montonide isa 51 VG
Description: Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric-001 500 mcg
Description: Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Multimeric-001 500mcg
Description: Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: Injection of the conventional flu vaccine: Vaxigrip to all study participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Injection of the conventional flu vaccine: Vaxigrip to all study participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Injection of the conventional flu vaccine: Vaxigrip to all study participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Injection of the conventional flu vaccine: Vaxigrip to all study participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Injection of the conventional flu vaccine: Vaxigrip to all study participants.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: Injection of the conventional flu vaccine: Vaxigrip to all study participants.
Study: NCT02349035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compare control of multifunction transradial prosthesis
Description: Subjects practice control methods using a VR system. EMG data and virtual games are used and provide data to assess control methods without prosthesis. Subjects are fit with commercially available multifunctional hand system. They receive 1-3 days of training for conventional or pattern recognition control. They return home for an 8 week trial. They use the prosthesis for 2 hours a day across the 8 week trial. They keep a log of use and check with a therapist about usage and performance. After the 8 week trial, data from the prosthesis is downloaded. The subject will complete 1-3 days of outcomes testing. They perform a series of tests and data is recorded. The subject will repeat the 1-3 days of training, 8 week home trial, and 1-3 days of outcomes testing with either type of control.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perform TMR surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.
Description: Subject has Targeted Muscle Reinnervation surgery. The surgery transfers median nerve to flexor digitorum superficialis muscle and ulnar nerve to flexor carpi ulnaris muscle. Two weeks after surgery, exercises start for muscle recovery. Then return to prosthesis from Phase 1 for 6 months. If they have pattern recognition control, usage and performance will be tracked for 6 months. If they return to conventional control, they will not complete tests, track usage, or performance. Six months after surgery, they return to pattern recognition control. Receive 1-3 days of training. Take prosthesis home for 8 week trial. Log use of device, note issues, and follow up with therapist. After home trial, 1-3 days of outcomes testing are completed and usage data downloaded. Continue using their prostheses for an additional 3-4 months. At 12 months after surgery, a final round of 1-3 days of testing and data are downloaded.
Study: NCT04608045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM
Description: CPX-POM
Study: NCT01121471

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA)
Description: 6.4 g CLA/day, capsule form, for 16 week arms

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower OIl
Description: 8.0g/day safflower oil
Study: NCT05236907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention was used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 7.5 mg of Midazolam orally.
Study: NCT04980014

Intervention type: DRUG
Intervention: NesinaAct® Tablet
Description: NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.
Study: NCT00678015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nordihydroguaiaretic Acid (NDGA)
Description: NDGA 2000mg daily
Study: NCT02999074

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Description: The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care during neoadjuvant chemotherapy/Exercise after surgery
Description: The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
Study: NCT04076943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per schedule specified in the arm description.
Study: NCT02842177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic group
Description: The speculum was placed into the vagina and the cervix was cleansed with povidone iodine. After placement of single toothed vulsellum on the anterior lip of the cervix, for traction and fixation of the uterus, the uterine sound was inserted for determination of uterine length and uterine position followed by Cu-IUD insertion. The duration of IUD insertion were reported.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic group
Description: The speculum was placed into the vagina and the cervix was cleansed with povidone iodine. After placement of single toothed vulsellum on the anterior lip of the cervix, for traction and fixation of the uterus, the uterine sound was inserted for determination of uterine length and uterine position followed by Cu-IUD insertion. The duration of IUD insertion were reported.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine sounding sparing group
Description: after bimanual examination, the same sonographer (Level II experience) performed transvaginal /US using a SonoAce X6 machine (Medison, Korea) with transvaginal probe (4-8 MHz frequency, using an average 6.5 MHz). Firstly, he evaluated the uterine position. Then, he measured the endometrial and cervical stripe lengths in the sagittal view of the uterus and summed to have the actual length of the uterus; by which the IUD tube was adjusted before insertion.The same speculum and vulsellum were used and the IUD was inserted directly into the uterine cavity.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cu-IUD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cu-IUD
Study: NCT02242097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03572426

Intervention type: OTHER
Intervention: genotyping all subjects
Description: genotyping using SNaPshot genotyping method.

Intervention type: OTHER
Intervention: genotyping all subjects
Description: genotyping using SNaPshot genotyping method.

Intervention type: OTHER
Intervention: genotyping all subjects
Description: genotyping using SNaPshot genotyping method.
Study: NCT04956874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FL-REACH
Description: The FL REACH intervention is a 6-session intervention designed to facilitate transition to care following delivery of a memory disorders diagnosis by a MDC team. The intervention focused on an approach that used a toolbox of strategies to tailor skills-based learning, knowledge transmission, and self-care strategies to dementia caregivers. This pilot study focuses on adapting the established REACH II intervention for translation to the clinical setting, with a focus not only on implementation of the key components of the program, but also on feasibility and sustainability. This is part of a stepped-care model that is being developed at the AdventHealth-Orlando MDC. Caregivers of patients will be referred to the FL REACH intervention for foundational training and skills-development.
Study: NCT02005575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Dexamethasone
Description: The standard of care is to use a regional block solution containing both decadron and bupivicaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02932540

Intervention type: OTHER
Intervention: change of head position
Description: patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission

Intervention type: OTHER
Intervention: change of head position
Description: patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission

Intervention type: OTHER
Intervention: change of head position
Description: patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission

Intervention type: OTHER
Intervention: change of head position
Description: patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission
Study: NCT02184975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Knife Conization with stitches
Description: In the research arm patients who underwent cold-knife conization of the cervix underwent hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. These sutures were held prior to the onset of cold conization of the cervix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold knife Conization without stitches
Description: In the research arm patients who underwent cold-knife conization of the cervix have not undergone hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. After patient anesthesia and routine antisepsis was performed, cold knife conization of the cervix was performed.
Study: NCT04204746

Intervention type: OTHER
Intervention: We will observe and evaluate the temperature and moisture in the respiratory circuit by a thermo-hygrometer.

Intervention type: OTHER
Intervention: We will observe and evaluate the temperature and moisture in the respiratory circuit by a thermo-hygrometer.
Study: NCT04297631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin Powder
Description: Everyone gets tobramycin powder.
Study: NCT00715559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cysteamine bitartrate
Description: All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
Study: NCT03268343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Cytisine 1.5 mg Film-Coated Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Cytisine 1.5 mg Film-Coated Tablets
Study: NCT02492165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
Description: 0.5 mL, Subcutaneous
Study: NCT02320708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACE) (1000 mg)
Description: 2 Test ACE 500 mg tablets taken orally one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial ACE (1000 mg)
Description: 2 ACE 500 mg caplets taken orally one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Ibuprofen (IBU) (400 mg)
Description: 2 IBU 200 mg soft-gels taken orally one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 placebo caplets for acetaminophen taken orally one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo caplets for acetaminophen taken orally one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 placebo caplets for acetaminophen taken orally one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 placebo soft-gels for ibuprofen taken orally one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo soft-gels for ibuprofen taken orally one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 placebo soft-gels for ibuprofen taken orally one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets for Test acetaminophen taken orally one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets for Test acetaminophen taken orally one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets for Test acetaminophen taken orally one time
Study: NCT03275207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: an equal volume of saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
Study: NCT04161235

Intervention type: DEVICE
Intervention: The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP
Description: The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
Study: NCT03205150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Film coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Film coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
Study: NCT03157674

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT02380365

Intervention type: DEVICE
Intervention: Electrocardiography
Description: Duration of intervention per patient/subject:~5 min, observation 6 months
Study: NCT03615261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies (Enhanced)
Description: The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy \& attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing \& strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions.
Study: NCT01285661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium warfarin
Description: Patients with early vein recanalization, as shown by ultrasonography, and repeatedly negative D-dimer will have anticoagulation discontinued. They will be followed-up for up to 4 years after recruitment in order to assess the rate of recurrent symptomatic VTE. In all other patients anticoagulation will not be discontinued.
Study: NCT01535677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin + Glucophage tablet fasted
Description: Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin IR FDC tablet fasted
Description: single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin + Glucophage tablet fed
Description: Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin IR FDC tablet fed
Description: single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
Study: NCT03289247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tissue adhesive (Leukosan®)
Description: Tissue ahaesive
Study: NCT02813928

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ccfDNA analysis
Description: The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance
Study: NCT01145365

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exam under anesthesia (EUA)
Description: EUA established drainage of perianal fistulas \&/or abscesses will be done before patient begins medical therapy with certolizumab (Cimzia)
Study: NCT02076204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting
Description: MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
Study: NCT02548377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT03103191

Intervention type: DIAGNOSTIC_TEST
Intervention: KL-6 levels
Description: Measure of KL-6 in serum

Intervention type: DIAGNOSTIC_TEST
Intervention: KL-6 levels
Description: Measure of KL-6 in serum